BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting com ...

LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces that preclinical data showing the wider therapeutic ...

Labroots’ virtual events enable individuals worldwide to connect and engage in groundbreaking scientific research from your ...